Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 273-281

  Fenske, Timothy S ^a   Zhang, Mei Jie ^a   Carreras, Jeanette ^a   Ayala, Ernesto ^b   Burns, Linda J ^d   Cashen, Amanda ^f   Costa, Luciano J ^g   Freytes, César O ^h   Gale, Robert P ⁱ   Hamadani, Mehdi ^a   Holmberg, Leona A ^k   Inwards, David J ^e   Lazarus, Hillard M ^l   Maziarz, Richard T ^m   Munker, Reinhold ⁿ   Perales, Miguel Angel ^o   Rizzieri, David A ^p   Schouten, Harry C ^q   Smith, Sonali M ^r   Waller, Edmund K ^s   Wirk, Baldeep M ^c   Laport, Ginna G ^t   Maloney, David G ^k   Montoto, Silvia ^j   Hari, Parameswaran N ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e MAYO CLINIC ROCHESTER   (United States)

^f BARNES JEWISH HOSPITAL   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p DUKE UNIVERSITY MEDICAL CENTER   (United States)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^s EMORY UNIVERSITY HOSPITAL   (United States)

^t STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HEMATOCRIT; HUMAN; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84897020212     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.2454     Document Type: Article

References (29)

1. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al: Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120:793-800, 2003 (Pubitemid 36315101)
2. Geisler CH, Kolstad A, Laurell A, et al: Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support - Still very long survival but late relapses do occur. Br J Haematol 158:355-362, 2012
3. Romaguera JE, Fayad LE, Feng L, et al: Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200-208, 2010
4. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005 (Pubitemid 46211378)
5. Nickenig C, Dreyling M, Hoster E, et al: Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107:1014-1022, 2006 (Pubitemid 44321684)
6. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood 119:2093-2099, 2012
7. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156:346-353, 2012
8. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004 (Pubitemid 39517009)
9. Tam CS, Bassett R, Ledesma C, et al: Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144-4152, 2009
10. Maris MB, Sandmaier BM, Storer BE, et al: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542, 2004 (Pubitemid 39564424)
11. Cook G, Smith GM, Kirkland K, et al: Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): A study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16:1419-1427, 2010
12. Le Gouill S, Kröger N, Dhedin N, et al: Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience. Ann Oncol 23:2695-2703, 2012
13. Hoster E, Metzner B, Forstpointner R, et al: Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009 (abstr 880)
14. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520-525, 2009
15. Reddy N, Greer JP, Goodman S, et al: Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp Hematol 40:359-366, 2012
16. Till BG, Gooley TA, Crawford N, et al: Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 49:1062-1073, 2008 (Pubitemid 351943251)
17. Delarue R, Haioun C, Ribrag V, et al: CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 121:48-53, 2013
18. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
19. Hamadani M, Saber W, Ahn KW, et al: Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: A cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 19:625-631, 2013
20. Zelenetz AD, Wierda WG, Abramson JS, et al: Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw 10:1487-1498, 2012
21. Budde LE, Guthrie KA, Till BG, et al: Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023-3029, 2011
22. Geisler CH, Kolstad A, Laurell A, et al: The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115:1530-1533, 2010
23. Martin P, Chadburn A, Christos P, et al: Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: Overall survival exceeding 7 years with standard therapies. Ann Oncol 19:1327-1330, 2008
24. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012
25. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 30:3119-3126, 2012
26. Habermann TM, Lossos IS, Justice G, et al: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145:344-349, 2009
27. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829, 2009
28. Hitz F, Martinelli G, Zucca E, et al: A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematol Oncol 27:154-159, 2009
29. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356, 2005 (Pubitemid 46206988)